Exploring Advantages to Third-Generation TKIs in Lung Cancer

February 1, 2019
Sukhmani Padda, MD

Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.

Sukhmani Padda, MD, assistant professor of medicine at Stanford University, discusses how third-generation EGFR tyrosine kinase inhibitors (TKIs) compare to the first- and second-generation TKIs.

Osimertinib (Tagrisso) is currently the only approved third-generation TKI, but this agent has dramatically changed the treatment landscape in lung cancer, says Padda.

Unlike earlier generation TKIs, the third-generation TKIs select for activity againstT709M